Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

doi:10.1038/nbt.1640

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Nature biotechnology - 1 Jun 2010

Singh Mallika, Lima Anthony, Molina Rafael, Hamilton Patricia, Clermont Anne C, Devasthali Vidusha, Thompson Jennifer D, Cheng Jason H, Bou Reslan Hani, Ho Calvin C K, Cao Timothy C, Lee Chingwei V, Nannini Michelle A, Fuh Germaine, Carano Richard A D, Koeppen Hartmut, Yu Ron X, Forrest William F, Plowman Gregory D, Johnson Leisa

Abstract excerpt

The low rate of approval of novel anti-cancer agents underscores the need for better preclinical models of therapeutic response as neither xenografts nor early-generation genetically engineered mouse models (GEMMs) reliably predict human clinical outcomes. Whereas recent, sporadic GEMMs emulate many aspects of their human disease counterpart more closely, their ability to predict clinical therapeutic responses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Deoxycytidine

Share to Erlotinib Hydrochloride

Share to Gemcitabine

Share to Genetic Engineering

Share to Quinazolines

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed

Identifiers

PMID: 20495549
DOI: 10.1038/nbt.1640

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.PMID 20495549Read ↗

Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial OutcomesSemantic proximity Read ↗

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Semantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.Semantic proximity Read ↗

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human CancersSemantic proximity Read ↗

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read ↗

Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?Semantic proximity Read ↗

Animal modeling of cancer pathology and studying tumor response to therapy.Semantic proximity Read ↗

Mouse Models of CancerSemantic proximity Read ↗

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.Semantic proximity Read ↗

Translation of Anticancer Efficacy From Nonclinical Models to the ClinicSemantic proximity Read ↗

Genetically Engineered Models Have Advantages over Xenografts for Preclinical StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.